Mr. Stephen Van Deventer reports

PREVECEUTICAL'S SUBSIDARY, BIOGENE THERAPEUTICS ANNOUNCES STRATEGIC APPOINTMENTS: DR. LINNEA OLOFSSON AS CHIEF SCIENTIFIC OFFICER AND DR. HARRY PAREKH AS CHIEF RESEARCH OFFICER

Preveceutical Medical Inc.'s wholly owned subsidiary, BioGene Therapeutics Inc., has appointed Dr. Linnea Olofsson as chief scientific officer and Dr. Harry Parekh as chief research officer, effective Nov. 16, 2024.

Stephen Van Deventer, chief executive officer of BioGene, commented: "The appointments of Dr. Olofsson and Dr. Parekh are pivotal milestones for BioGene as we position ourselves at the forefront of scientific innovation and leadership in the life sciences sector. Harry's visionary contributions to drug and gene delivery technologies, coupled with Linnea's profound expertise and interdisciplinary approach, will undoubtedly propel our company into its next phase of growth and success."

Dr. Parekh -- driving innovation in drug and gene delivery systems

Dr. Parekh is a recognized leader in pharmaceutical chemistry and its application in the formulation of advanced drug/gene delivery platform systems. His groundbreaking work at the University of Queensland's School of Pharmacy leverages over two decades of experience; this spans the design, development and validation of innovative chemistries/formulations for tissue-targeted, controlled and sustained therapeutic delivery. His pursuits have focused on addressing critical challenges and bottlenecks impeding the translation of precision medicine for both rare and mainstream disease. As CRO, Dr. Parekh will oversee the validation and translation of BioGene's innovative research platforms into real-world therapeutic applications, assuring the company's technologies achieve maximum impact, benefit and reach for patients globally.

Dr. Olofsson -- bridging science and strategy

Dr. Olofsson brings a wealth of experience as an accomplished biophysicist with expertise spanning oncology, molecular biology, CRISPR-Cas9 gene editing and advanced microscopy techniques. Her extensive knowledge of time-resolved microscopy and spectroscopy, single-molecule detection, and fluorescence superresolution microscopy, structure-based drug design and dynamics, pharmacology, and cell biology underpins her scientific acumen. Dr. Olofsson's interdisciplinary approach and collaborative work with Dr. Parekh have provided her with a comprehensive understanding of BioGene's scientific priorities and opportunities for innovation.

Dr. Olofsson has demonstrated a remarkable ability to align complex scientific research with strategic objectives, facilitating the advancement of cutting-edge therapies. Her focus as CSO will be on steering BioGene's scientific initiatives to align with its mission to deliver transformative treatments, ensuring robust scientific integrity and excellence.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature-identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

About BioGene Therapeutics Inc.

BioGene is a Texas-based life science company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5-per-cent R&D tax cashback incentive. This subsidiary supports continuing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies designed to address the growing global diabetes and obesity crisis.

We seek Safe Harbor.